Study shows wide variation in head and neck cancer care

Source: www.cancerresearchuk.org Author: staff Just three in every hundred head and neck cancer patients in England receive the ideal standard of care, according to a new study. The National Head and Neck Cancer Audit found wide variations in care, with just 3.1 per cent of patients receiving every element of care deemed important by experts. Sara Osborne, head of policy at Cancer Research UK, said it was "disappointing" to see such variation in care for patients with head and neck cancers. But the figures also show there has been an improvement in survival rates among head and neck cancer patients over the last two years, despite variations in care. The Ideal Patient Pathway contains seven elements of "holistic and integrated care" such as nutritional, speech and language and dental assessments and chest scans or x-rays before surgery. It also involves people's disease being discussed by a multi-disciplinary team including specialist surgeons, oncologists, speech therapists and nursing staff. Researchers examined data submitted by all head and neck cancer teams in England and Wales, relating to the care of 8,100 patients between November 2011 and October 2012. They found that the largest group of patients (24.7 per cent) received three elements of the Ideal Patient Pathway, with some aspects delivered more consistently than others. For example, 96.4 per cent of surgical head and neck cancer patients had their case discussed by a multi-disciplinary team, but just 18.8 per cent had an assessment with a speech and language therapist before surgery. The findings [...]

Interim results from CEL-SCI’s Multikine Phase III study on head and neck cancer

Source: www.news-medical.net CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns. The IDMC also indicated that no safety signals were found that would call into question the benefit/risk of continuing the study. CEL-SCI considers the results of the IDMC review to be important since studies have shown that up to 30% of Phase III trials fail due to safety considerations and the IDMC's safety findings from this interim review were similar to those reported by investigators during CEL-SCI's Phase I-II trials. Ultimately, the decision as to whether a drug is safe is made by the FDA based on an assessment of all of the data from a trial. IDMCs are committees commonly used by sponsors of clinical trials to protect the interests of the patients in ongoing trials especially when the trials involve patients with life threatening diseases, and when, as in cancer clinical trials, they extend over long periods of time (3-5 years). The committee's membership should include physicians and clinical trial scientists knowledgeable in the appropriate disciplines, including statistics. The CEL-SCI IDMC includes prominent physicians and scientists from major institutions in the USA and abroad who are key opinion leaders in head and neck cancer and who are knowledgeable in all of the disciplines related to CEL-SCI's study, including statistics. The Multikine Phase III study is enrolling [...]

Go to Top